Inhibikase Therapeutics (IKT) EBT Margin (2020 - 2023)
Inhibikase Therapeutics' (IKT) quarterly EBT Margin came in at 440356600.0% in Q4 2023, down 44034978036.0% year-on-year from N/an in Q4 2022, and down 7297886.32% on a QoQ basis from 6033.95% in Q3 2023.
Inhibikase Therapeutics (IKT) EBT Margin (2020 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has 4 years of EBT Margin data on file, last reported at 440356600.0% in Q4 2023.
- On a quarterly basis, EBT Margin fell 44034978036.0% year-over-year to 440356600.0% in Q4 2023; TTM through Sep 2024 was 2042608500.0%, a 204260228406.0% decrease from a year earlier, with the FY2023 full-year figure at 7712.68%, up 1700723.0% from the prior year.
- EBT Margin for Q4 2023 stood at 440356600.0%, down from 6033.95% in the prior quarter.
- Over the last five years, EBT Margin for IKT reached as high as 187.4% in Q1 2021 and fell as low as 440356600.0% in Q4 2023.
- Historically, EBT Margin has averaged 27549294.57% across 4 years, with a median of 5698.43% in 2023.
- Across the five-year window, EBT Margin soared 25155711 bps in 2022 and sank 2000000000 bps in 2023, its largest moves.
- Year by year, EBT Margin stood at 708.85% in 2020, then sank by 36350 bps to 258376.75% in 2021, then soared by 97 bps to 6819.64% in 2022, then sank by 6457080 bps to 440356600.0% in 2023.
- Per Business Quant data, the three most recent EBT Margin figures were 440356600.0% in Q4 2023, 6033.95% in Q3 2023, and 5362.92% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -440,356,600.00% |
| Sep 30, 2023 | -6,033.95% |
| Jun 30, 2023 | -5,362.92% |
| Mar 31, 2023 | -7,384.64% |
| Dec 31, 2022 | -6,819.64% |
| Sep 30, 2022 | -62,609.53% |
| Jun 30, 2022 | -70,817.14% |
| Mar 31, 2022 | -10,083.57% |
| Dec 31, 2021 | -258,376.75% |
| Sep 30, 2021 | -1,361.26% |
| Jun 30, 2021 | -193.40% |
| Mar 31, 2021 | -187.40% |
| Dec 31, 2020 | -708.85% |
| Sep 30, 2020 | -1,779.72% |
| Jun 30, 2020 | -192.12% |
| Mar 31, 2020 | -202.17% |